BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 5, 2026
$8,17
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$6,00minimo 52 sett.
$11,22massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
Ricavi (TTM)
$941M
i tuoi badge
Intervallo 52 sett.
$6–$11
Rating Analisti
BUY
Prezzo Obiettivo
$21
P/E
-5.5
ROE
87.8%
Margine di Profitto Netto
-40.9%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
BCRX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$8.17
Capitalizzazione di Mercato (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
Ricavi (TTM)
$941M
ROE (TTM)
87.8%
D/E Debito/Patrimonio (MRQ)
-0.9
Intervallo 52 sett.
$6–$11
BCRX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Informazioni su BioCryst Pharmaceuticals, Inc. - Common Stock Panoramica della società da Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaBiotechnology
dipendenti435
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
Flusso di cassa libero$345M2016-12-31 → 2025-12-31
Margine netto-40.9%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | BCRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -5.5media 5 anni ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.2media 5 anni ≈6.7 | ≈6.7 | 29.2 | Sottovalutato | |
| P/B (MRQ) | -4.6media 5 anni ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.3media 5 anni ≈-281.5 | ≈-281.5 | · | · | |
| Prezzo / FCF (TTM) | 5.6media 5 anni ≈-13.6 | ≈-13.6 | · | · | |
| Prezzo / Flusso di cassa (TTM) | 5.5media 5 anni ≈-13.9 | ≈-13.9 | · | · | |
| EV / Ricavi (TTM) | 2.3media 5 anni ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.7media 5 anni ≈-14.4 | ≈-14.4 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | BCRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | -33.3%media 5 anni ≈-32.2% | ≈-32.2% | -1041.7% | Di prim'ordine | |
| EBITDA Margin (Margine EBITDA) | 39.1%media 5 anni ≈-31.8% | ≈-31.8% | -1041.7% | Di prim'ordine | |
| Margine ante imposte (TTM) | -40.5%media 5 anni ≈-52.6% | ≈-52.6% | -493.4% | Di prim'ordine | |
| Margine di Profitto Netto (TTM) | -40.9%media 5 anni ≈-53.3% | ≈-53.3% | -990.1% | Di prim'ordine | |
| ROA (TTM) | -75.8%media 5 anni ≈-18.2% | ≈-18.2% | -40.3% | Di prim'ordine | |
| ROE (TTM) | 87.8%media 5 anni ≈42.1% | ≈42.1% | -55.6% | Debole | |
| ROIC | -282.4%media 5 anni ≈-118.5% | ≈-118.5% | -55.2% | Debole |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | BCRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | -0.9media 5 anni ≈-0.7 | ≈-0.7 | 0.0 | Basso indebitamento | |
| Rapporto corrente (MRQ) | 2.3media 5 anni ≈3.7 | ≈3.7 | 6.7 | Bassa liquidità | |
| Quick Ratio (MRQ) | 2.2media 5 anni ≈2.5 | ≈2.5 | 4.5 | Bassa liquidità | |
| Debito a lungo termine / Patrimonio netto (MRQ) | -0.9media 5 anni ≈-0.7 | ≈-0.7 | 0.2 | Basso indebitamento |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | BCRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 94.1%media 5 anni ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 47.8%media 5 anni ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 117.9% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | BCRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 1.7media 5 anni ≈0.8 | ≈0.8 | 0.1 | Di prim'ordine | |
| Inventory Turnover (Rotazione delle scorte) | 2.8media 5 anni ≈0.9 | ≈0.9 | · | · | |
| Receivables Turnover (Rotazione dei crediti) | 9.4media 5 anni ≈7.4 | ≈7.4 | · | · | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$2.0M | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
23.2%
Prossimo report
Nov 02, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31 Marzo 2026 | $-0.09 | $0.05 | -281.8% | |
| 31 Dicembre 2025 | $0.01 | $0.04 | -74.1% | |
| 30 Settembre 2025 | $0.06 | $0.04 | 67.1% | |
| 30 Giugno 2025 | $0.04 | $0.01 | 179.7% | |
| 31 Marzo 2025 | $0.00 | $-0.07 | 100.0% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $875M | $451M | $331M | $271M | $157M |
| Margine Operativo % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Utile netto | $264M | $-89M | $-227M | $-247M | $-184M |
| EPS Diluito | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Rapporto corrente | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $345M | $-53M | $-97M | $-163M | $-145M |
Proprietari istituzionali (13F) 346 filer · $2.8B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
346
Valore detenuto
$2.8B
Nuove posizioni
55
Posizioni chiuse
34
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 55 (-22 vs trimestre precedente) | 34 (-5 vs trimestre precedente) | 137 (+20 vs trimestre precedente) | 87 (+8 vs trimestre precedente) | +4.1M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $238.930.360 | 23.893.036 | 8,46% | Azioni |
| VANGUARD GROUP INC | $173.732.325 | 22.273.375 | 6,15% | Azioni |
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 5,61% | Azioni |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 5,38% | Azioni |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 5,35% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 4,03% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 3,95% | Azioni |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 3,90% | Azioni |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 3,65% | Azioni |
| JANUS HENDERSON GROUP PLC | $84.853.520 | 8.908.506 | 3,01% | Azioni |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 2,94% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 2,40% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $62.493.232 | 6.248.046 | 2,21% | Azioni |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 1,88% | Azioni |
| UBS Group AG | $50.782.800 | 5.078.280 | 1,80% | Azioni |
| BANK OF AMERICA CORP /DE/ | $48.012.840 | 4.801.284 | 1,70% | Azioni |
| GOLDMAN SACHS GROUP INC | $44.818.738 | 4.481.874 | 1,59% | Azioni |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,42% | Azioni |
| Nuveen, LLC | $40.072.370 | 4.007.237 | 1,42% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,20% | Azioni |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,13% | Azioni |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,02% | Azioni |
| JANE STREET GROUP, LLC | $27.626.830 | 2.762.683 | 0,98% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $27.187.810 | 2.718.781 | 0,96% | Azioni |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 0,92% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 0,90% | Azioni |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 0,89% | Azioni |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 0,89% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 0,83% | Azioni |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 0,83% | Azioni |
| NORTHERN TRUST CORP | $22.557.310 | 2.255.731 | 0,80% | Azioni |
| AQR CAPITAL MANAGEMENT LLC | $22.143.020 | 2.214.302 | 0,78% | Azioni |
| MORGAN STANLEY | $19.996.852 | 1.999.684 | 0,71% | Azioni |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,67% | Azioni |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,66% | Azioni |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,66% | Azioni |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,65% | Azioni |
| STIFEL FINANCIAL CORP | $18.262.340 | 1.826.234 | 0,65% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,62% | Azioni |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,62% | Azioni |
| JUPITER ASSET MANAGEMENT LTD | $16.428.740 | 1.642.874 | 0,58% | Azioni |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,58% | Azioni |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,58% | Azioni |
| Legal & General Group Plc | $14.555.141 | 1.455.514 | 0,52% | Azioni |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,48% | Azioni |
| Invesco Ltd. | $12.337.830 | 1.233.783 | 0,44% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,42% | Azioni |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,42% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,42% | Azioni |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,40% | Azioni |
Attivisti e proprietari del 5%+ 15 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 depositi | 31 Luglio 2018 | · | Deposito iniziale | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 02 Aprile 2018 | · | Deposito iniziale | Investimento passivo | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 depositi | 16 Agosto 2016 | · | Deposito iniziale | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 depositi | 23 Ottobre 2012 | · | Deposito iniziale | M&A / vendita | SEC |
| Julian C. Baker, Felix J. Baker ×4 depositi | 13 Ottobre 2011 | · | Deposito iniziale | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 depositi | 20 Agosto 2007 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 07 Dicembre 2005 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 07 Dicembre 2005 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 07 Dicembre 2005 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 13 Ottobre 2005 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 26 Febbraio 2004 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 25 Febbraio 2004 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 24 Febbraio 2004 | · | Deposito iniziale | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 depositi | 31 Ottobre 2003 | · | Deposito iniziale | · | SEC |
| William W. Featheringill | 14 Febbraio 2002 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 51 insider · 21 dirigenti · 30 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 Dicembre 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 Dicembre 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 Febbraio 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 Marzo 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 Dicembre 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 Marzo 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 Maggio 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 06 Aprile 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 Marzo 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 Dicembre 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 Novembre 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 Marzo 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 Dicembre 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 Gennaio 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 Marzo 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 07 Febbraio 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 Marzo 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 Luglio 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 Luglio 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 Luglio 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 Maggio 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Direttore | 31 Agosto 2026 A | 47.821 | 0 | 1 | $-100.285 |
| Jill C. Milne | Direttore | 31 Agosto 2026 A | 33.226 | 0 | 0 | $0 |
| Steven Frank | Direttore | 31 Agosto 2026 A | 36.747 | 0 | 0 | $0 |
| Jon P Stonehouse | Direttore | 31 Agosto 2026 A | 1.340.419 | 0 | 0 | $0 |
| Vincent Milano | Direttore | 31 Agosto 2026 A | 109.642 | 0 | 0 | $0 |
| Theresa Heggie | Direttore | 11 Giugno 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Direttore | 11 Giugno 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Steven K Galson | Direttore | 11 Giugno 2026 A | 27.794 | 0 | 0 | $0 |
| Alan G Levin | Direttore | 11 Giugno 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Direttore | 12 Giugno 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Direttore | 12 Giugno 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Direttore | 12 Giugno 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Direttore | 13 Giugno 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direttore | 28 Febbraio 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Direttore | 28 Novembre 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Direttore | 20 Giugno 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Direttore | 24 Maggio 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | Direttore | 29 Febbraio 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Direttore | 02 Maggio 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Direttore | 23 Maggio 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Direttore | 23 Maggio 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Direttore | 12 Maggio 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Direttore | 13 Maggio 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Direttore | 13 Maggio 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Direttore | 16 Maggio 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Direttore | 16 Maggio 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Direttore | 18 Marzo 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Direttore | 17 Maggio 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Direttore | 04 Novembre 2003 M | 46.785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21 Maggio 2008 A | · | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 41 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,35% | 1.193.733 SH | 01 Ottobre 2026 | Giornaliero |
| BBP · ETFis Series Trust I | 1,42% | 155.993 NS | 31 Luglio 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0,99% | 510 NS | 31 Luglio 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,92% | 1.078.429 NS | 31 Luglio 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 248.560 NS | 31 Luglio 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,59% | 324.702 NS | 31 Luglio 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,36% | 516.595 NS | 31 Luglio 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,23% | 73.039 SH | 01 Ottobre 2026 | Giornaliero |
| PWS · Pacer Funds Trust | 0,17% | 4.436 NS | 31 Luglio 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 19 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,14% | 18.119 SH | 01 Ottobre 2026 | Giornaliero |
| ESSC · Strategy Shares | 0,14% | 5.593 NS | 31 Luglio 2026 | N-PORT |
| IBB · iShares Trust | 0,13% | 1.651.139 SH | 11 Settembre 2026 | Giornaliero |
| IWO · iShares Trust | 0,13% | 2.178.966 SH | 11 Settembre 2026 | Giornaliero |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 174.467 NS | 31 Luglio 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 64.429 NS | 31 Luglio 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 46.799 NS | 31 Luglio 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 19 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,07% | 111.471 NS | 31 Luglio 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 75.067 SH | 11 Settembre 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 207.179 SH | 01 Ottobre 2026 | Giornaliero |
| IWM · iShares Trust | 0,06% | 5.937.121 SH | 11 Settembre 2026 | Giornaliero |
| DFAS · Dimensional ETF Trust | 0,05% | 770.732 NS | 31 Luglio 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 19 Agosto 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 19 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 19 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 99.007 NS | 31 Luglio 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 19 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,01% | 11.812 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,00% | 72.998 SH | 11 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,00% | 336.323 SH | 11 Settembre 2026 | Giornaliero |
| DFUS · Dimensional ETF Trust | 0,00% | 52.194 NS | 31 Luglio 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.571 NS | 31 Luglio 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 Luglio 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 286 NS | 31 Luglio 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 19 Agosto 2026 | Giornaliero |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 196.622 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 19.676 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,00% | 51.624 SH | 19 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | · | 10.494 SH | 11 Settembre 2026 | Giornaliero |
| SMLF · iShares Trust | · | 766.086 SH | 11 Settembre 2026 | Giornaliero |
BCRX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 17 analisti
COMPRA
Target mediano
$17.00
+108,1%
5 29,4%
Acquisto forte
10 58,8%
Compra
2 11,8%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
11 analisti · 2026-09-28Target medio $20.64 +152,6%
← Sotto tutti i target
Prezzo attuale $8.17
Basso$11.00
Media$20.64
Alto$32.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
Ultime notizie Notizie recenti che menzionano questa società
RBC Capital Alza PT BioCryst Pharmaceuticals (BCRX) come parte della anteprima dei risultati Q1 2026 nel settore Biotech
Yahoo Finance · 5 mesi fa
BioCryst (BCRX) balza del 7,10% sulle voci di acquisizione
Yahoo Finance · 6 mesi, 1 settimana fa
BioCryst Pharmaceuticals, Inc. (BCRX) Un Buon Azionista Da Comprare Ora?
Yahoo Finance · 6 mesi, 1 settimana fa
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 5, 2026